Furthermore, the combination of ICGA-A and PD-1/PD-L1 inhibitor 2 exhibited superior tumor-suppressive effects compared to PD-1/PD-L1 inhibitor 2 alone, suggesting the potential of this combination as a therapeutic strategy for TNBC (Figures 5D-F). The gene discussed is CD274; the disease is neoplasm.